Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance ...

President Donald Trump announced nine of the largest drugmakers in the U.S. and Europe agreed to voluntarily sell their ...

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

But in rare cases, this class of drugs called GLP-1 agonists can come with a debilitating side effects. Chief among them is ...

Bank of America reaffirmed its Buy rating for Eli Lilly, setting a price target of $1,268. Analyst Jason Gerberry noted that the trial data strengthens the company's competitive stance against rival ...